AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11892710
Drug: Neridronate 25
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neridronate 25 mg
Trial: 11892710
Drug: Neridronate 50
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neridronate 50 mg
Trial: 21130385
Drug: Omalizumab (minimum,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (minimum, 0.016 mg/kg/IU (IgE/mL) every 4 weeks)
Trial: 11096224
Drug: Rivastigmine (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (6-12 mg/day)
Trial: 12413703
Drug: Phytodrug (QG-5)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytodrug (QG-5) from guava leaves, 500 mg capsules administered every 8 hours for 3 days
Trial: 2109467
Drug: Midazolam with
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam with low doses of phenoperidine for sedation and amnesia during cataract surgery
Trial: 7247000
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg piritramide
Trial: 7247000
Drug: 0.003 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.003 mg/kg fentanyl
Trial: 29131352
Drug: Intravenous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ethanol infusion at 100 mg%
Trial: 29131352
Drug: Intravenous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ethanol infusion at higher doses
Trial: 26291199
Drug: Selexipag (compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (compound 26a)
Trial: 24831989
Drug: Intensified insulin-based
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin-based glycaemic control for at least 3 months
Trial: 24831989
Drug: Conventional glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose-lowering treatment (Control)
Trial: 17324253
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine acupuncture-care and self-care (10 sessions over 12 weeks)
Trial: 17324253
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine acupuncture-care and self-care
Trial: 11445753
Drug: Exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise treatment group, met three times/week throughout the study
Trial: 8280654
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 160 mg daily
Trial: 25919112
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (1000 μg daily) for 4 weeks
Trial: 25919112
Drug: rs7772821 (T>G)
RxNorm normalized name: (T,G)-A-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs7772821 (T>G) polymorphism
Trial: 22194988
Drug: Low-dose flutamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose flutamide, metformin, and pioglitazone in combination with an estro-progestagen
Trial: 11169056
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2a 6 million units three times weekly plus ribavirin 14 mg/kg per day (n=93)
Trial: 8250106
Drug: Quinine (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (17 mg/kg over 4.5 hr)
Trial: 8250106
Drug: Prochlorperazine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (12.5 mg intramuscularly)
Trial: 30230694
Drug: Oral cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cabotegravir 30 mg after a high-fat meal (∼53% fat, ∼870 kcal)
Trial: 30230694
Drug: Oral cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cabotegravir 30 mg after fasting
Trial: 19250003
Drug: Intravenous micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous micronutrient therapy (IVMT)
Trial: 17827929
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg daily for 48 weeks)
Trial: 17827929
Drug: Alfacalcidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (0.5 microg daily for 48 weeks)
Trial: 3278581
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg twice daily)
Trial: 7946944
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg twice daily)
Trial: 26019023
Drug: Low-fat spread
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat spread enriched with plant sterols (PS) and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at doses of 0.0, 0.9, 1.3, and 1.8 g/day for 4 weeks
Trial: 21452357
Drug: Active PEMF
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PEMF treatment (pulsing electromagnetic field) worn on the distal forearm for 1, 2, or 4 hours/day for 8 weeks.
Trial: 21452357
Drug: Sham PEMF
RxNorm normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham PEMF treatment (identical sham transducers) worn on the distal forearm for 1, 2, or 4 hours/day for 8 weeks.
Trial: 21452357
Drug: Both active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both active and sham PEMF treatments.
Trial: 18472364
Drug: First booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First booster dose (46-70 Gy)
Trial: 18472364
Drug: Dose in
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose in the superior constrictor muscle
Trial: 10739508
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol valerate with 2.5 mg medroxyprogesterone acetate
Trial: 10739508
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol valerate with 5 mg medroxyprogesterone acetate
Trial: 10739508
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol valerate with 2.5 mg medroxyprogesterone acetate
Trial: 10739508
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol valerate with 5 mg medroxyprogesterone acetate
Trial: 10739508
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol valerate increased to 2 mg after 6 months with 2.5 mg medroxyprogesterone acetate
Trial: 10739508
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol valerate increased to 2 mg after 6 months with 5 mg medroxyprogesterone acetate
Trial: 3658907
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (2 l/min overnight from 22 hrs to 6 hrs)
Trial: 21148267
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment programme
Trial: 18186995
Drug: Budesonide/formoterol 200/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 200/6 microg one puff once daily and as required (active group)
Trial: 18186995
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg one puff twice daily plus their own short‐acting beta(2)‐agonist as required (control group)
Trial: 16603852
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg each night)
Trial: 11115733
Drug: Acute antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute antipsychotic drug administration
Trial: 8833207
Drug: Pamidronate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60 mg, intravenously)
Trial: 8833207
Drug: Clodronate (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (1500 mg, intravenously)
Trial: 8833207
Drug: Ibandronate (0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (0.5-2 mg, intravenously)
Trial: 29705445
Drug: Control (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (500 mg capsules containing starch)
Trial: 22644009
Drug: Glycophosphopeptical (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycophosphopeptical (1 g every 8 hours for 4 weeks)
Trial: 19057628
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with local anesthetic (lidocaine 0.5%)
Trial: 21102963
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of 6 mg non-particulate Celestone
Trial: 14765609
Drug: Fluoridated bonding
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated bonding agent with fluoridated composite resin (Group III)
Trial: 14765609
Drug: Non‐fluoridated bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐fluoridated bonding agent with fluoridated composite (Group II)
Trial: 14765609
Drug: Fluoridated bonding
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated bonding agent with non‐fluoridated composite (Group I)
Trial: 18445178
Drug: Captopril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (100 mg) alone
Trial: 10391396
Drug: Captopril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (100 mg) in combination with bendrofluazide (2.5 mg)
Trial: 1706501
Drug: Ticlopidine 250
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 250 mg/day (group A)
Trial: 15759454
Drug: Moxonidine 0.4
RxNorm normalized name: moxonidine 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.4 mg/day
Trial: 7046699
Drug: Flurazepam 15mg
DrugBank: Flurazepam (DB00690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurazepam 15mg daily for 14 days
Trial: 31141445
Drug: Medicine ball
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine ball plyometric training (8 weeks, thrice per week)
Trial: 21590273
Drug: 0.6 mL
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mL of 4% articaine with 1:100,000 epinephrine
Trial: 21590273
Drug: 0.9 mL
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mL of 4% articaine with 1:100,000 epinephrine
Trial: 21590273
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL of 4% articaine with 1:100,000 epinephrine
Trial: 19594937
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg once daily (QD)
Trial: 19594937
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 100 microg twice daily (BID)
Trial: 19594937
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate metered dose inhaler (BDP-MDI) 168 microg BID
Trial: 17577003
Drug: 54 mg
RxNorm normalized name: aspirin 454 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54 mg of genistein daily for 24 months
Trial: 12186624
Drug: Bicalutamide monotherapy
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide monotherapy
Trial: 9726277
Drug: Sustained-release naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release naltrexone (NTX) 206 mg subcutaneous injection
Trial: 10439
Drug: Antirheumatic drugs
RxNorm normalized name: Quinolines, antirheumatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antirheumatic drugs
Trial: 10439
Drug: Pain response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pain response measured using a daily pain chart
Trial: 27053574
Drug: Structured patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured patient education ambulatory program combined with weekly sessions of dance therapy
Trial: 25095738
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with clopidogrel (75 mg) plus aspirin (300 mg)
Trial: 25095738
Drug: Aspirin monotherapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin monotherapy (300 mg)
Trial: 23358123
Drug: Exenatide once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide once weekly (ExQW) 2 mg
Trial: 17400593
Drug: PAIS (Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAIS (Paracetamol in Stroke)
Trial: 15200749
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zoledronic acid intravenously yearly
Trial: 15200749
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion yearly
Trial: 7826961
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (verum)
Trial: 3396401
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (single dose)
Trial: 3396401
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (1-2 weeks of therapy)
Trial: 3396401
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (Group 1)
Trial: 3396401
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (Group 2)
Trial: 29457876
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg single dose
Trial: 27297718
Drug: Curcumin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1000 mg/d)
Trial: 21122699
Drug: ERN/LRPT 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERN/LRPT 1 g
Trial: 11814493
Drug: Vaginal metronidazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal metronidazole, 37.5 mg twice daily for 5 days
Trial: 11814493
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel twice daily for 5 days
Trial: 6994789
Drug: Inert preparation
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert preparation (placebo)
Trial: 31552981
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg free EA
Trial: 31552981
Drug: 237 mL
RxNorm normalized name: ALCOHOL 189.6 mL in 237 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 237 mL PomJ (∼120 mg of EA)
Trial: 9815298
Drug: All arms
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All arms received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15.
Trial: 7708002
Drug: octreotide (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octreotide (daily doses between 100 and 1000 micrograms)
Trial: 31315910
Drug: O-sulfo-l-tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-sulfo-l-tyrosine
Trial: 26305143
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tolterodine ER
Trial: 26305143
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg tolterodine ER
Trial: 7851032
Drug: Lisinopril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (mean dose: 6.4 +/- 4 mg) for 6 months
Trial: 29111784
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (BLT) only
Trial: 29111784
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bright Light Therapy (BLT) and Wake Therapy (WT)
Trial: 28195995
Drug: TX-004HR (4-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-004HR (4-, 10-, and 25-μg)
Trial: 23446684
Drug: Pridopidine 90
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 90 mg/day
Trial: 18440821
Drug: Everolimus (0.75-10mg)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (0.75-10mg) daily for 21 days
Trial: 12648202
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of hyperbaric bupivacaine + 10 microg fentanyl (B3F)
Trial: 12648202
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of hyperbaric bupivacaine (B4)
Trial: 16198237
Drug: Edaravone (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (administered to 27 patients: GIa, n = 13; GIIa, n = 14)
Trial: 2321570
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation (65 mg/d for 2 weeks, 5 mg/d for 4 weeks, 605 mg/d for 3 weeks, 5 mg/d for 4 weeks, average 375 mg/d for 1 week)
Trial: 28296581
Drug: Alectinib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib 300 mg orally twice per day
Trial: 26255281
Drug: Beta-alanine (BA)
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (BA) supplementation (800 mg BA + 8 g dextrose, 4 doses/day for 28 days)
Trial: 26255281
Drug: Placebo (PLA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA; 8 g dextrose, 4 doses/day for 28 days)
Trial: 20947819
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg/d)
Trial: 20947819
Drug: Metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2 g/d)
Trial: 16973786
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) over 6 months
Trial: 16973786
Drug: Monthly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly monitoring
Trial: 9631952
Drug: Pergolide (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (0.05 mg BID) for 8 days
Trial: 23314060
Drug: Biological pathway
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological pathway analysis
Trial: 14747190
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet/day)
Trial: 18361342
Drug: Oral-B Triumph
RxNorm normalized name: Triumph
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Triumph
Trial: 18361342
Drug: Combined overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined overall treatment effect from two studies
Trial: 12708602
Drug: SB-LOT (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-LOT (90 mg coumarin + 540 mg troxerutin/d)
Trial: 8715321
Drug: Technique of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique of drop administration taught to patients
Trial: 1396198
Drug: Nimorazole 4G
RxNorm normalized name: nimorazole
DrugBank: Nimorazole (DB12172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimorazole 4G in two equally divided doses 24 hours apart (2GBD)
Trial: 24831919
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (BG: 70‐110 mg/dL)
Trial: 24831919
Drug: Standard glycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glycemic control (BG: 70‐180 mg/dL)
Trial: 19644691
Drug: Ultrasound (US)
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US) treatment and exercises
Trial: 16008114
Drug: Korodin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korodin (25 drops, applied once, followed by daily 3 x 25 drops for 7 days)
Trial: 16008114
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single application and daily treatment for 7 days)